U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

In a lawsuit filed in Delaware Chancery Court, Pfizer said Novo Nordisk’s offer can’t be considered superior because it isn’t ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Pfizer has decided to sue Metsera and Novo over $8.5B bid, citing antitrust risks and asserting regulatory advantage.

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Denmark's Novo Nordisk launched a rival bid for U. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

A bidding war has broken into the open for the obesity-focused Metsera, with Novo Nordisk aiming to outbid Pfizer for the ...